ClinicalTrials.govpublic full text
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
leukemia, myeloid, myelodysplastic syndromes, lenalidomide, hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 803198
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.